【レポートの概要（一部）】
1. Report Overview
1.1 Global Asthma and COPD Therapies Market Overview
1.2 Global Asthma and COPD Therapies Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2. Introduction to Asthma and COPD Therapies
2.1 The Pharmaceutical Industry: A Very Brief Overview
2.2 Overview of Respiratory Diseases
2.2.1 Classifying Respiratory Diseases: Obstructive and Restrictive
2.3 What Is Asthma?
2.3.1 Trends in Asthma Prevalence
2.3.2 Pathophysiology of Asthma
2.3.3 Symptoms of Asthma
2.3.4 Causes and Triggers for Asthma
2.3.5 Treatment of Asthma
2.3.6 Guidelines for Asthma Treatment
2.3.7 Drug Treatments for Asthma
2.3.8 Drug Delivery Methods in Asthma
2.4 What Is Chronic Obstructive Pulmonary Disease (COPD)?
2.4.1 Trends in COPD Prevalence
2.4.2 Pathophysiology of COPD
2.4.3 Signs and Symptoms of COPD
2.4.4 Treatment of COPD
2.4.5 Drug Treatments for COPD
2.4.6 Guidelines for COPD Treatment
2.5 Major Drug Classes in the Treatment of Asthma and COPD
2.5.1 Bronchodilators
2.5.1.1 Beta2-Agonists
2.5.1.2 Anticholinergics
2.5.2 Anti-Inflammatory Drugs
2.5.2.1 Corticosteroids
2.5.2.2 Leukotriene Receptor Antagonists
2.5.2.3 Monoclonal Antibodies in the Treatment of Respiratory Disease
2.5.3 Combination Drugs
2.6 Phases of Clinical Trials
2.7 Scope of this Report
2.8 Currency Exchange Rates in This Report
3. Asthma and COPD Therapies: World Market 2015-2025
3.1 The World Respiratory Drugs Market by Therapeutic Area
3.2 The World Asthma and COPD Therapies Market in 2014
3.2.1 Leading Asthma and COPD Therapies
3.2.2 Leading Companies in the Asthma and COPD Therapies Market
3.3 World Asthma and COPD Therapies Market: Sales Forecast by Therapeutic Area, 2015-2025
3.3.1 World Asthma Therapies Market: Sales Forecast 2015-2025
3.3.2 World COPD Therapies Market: Sales Forecast 2015-2025
3.4 World Asthma and COPD Therapies Market: Sales Forecast by Drug Class 2015-2025
3.5 Combination Drugs Lead the Asthma and COPD Therapies Market
3.6 How Will Segmental Market Shares Change to 2025?
3.6.1 World Asthma and COPD Therapies Market: Drivers and Restraints 2015-2025
3.7 Asthma and COPD Therapies: Trends and Developments
3.7.1 FDA Requires Replacement of CFC Inhalers with HFA Inhalers
3.7.2 The WISDOM Trial: Will Steroids Lose Their Role in COPD?
4. Leading National Markets 2015-2025
4.1 Regional Breakdown of the World Asthma and COPD Therapies Market
4.2 World Asthma and COPD Therapies Market: Regional Forecast 2015-2025
4.2.1 How Will Regional Market Shares Change to 2025?
4.3 National Breakdown of the World Asthma and COPD Therapies Market
4.4 World Asthma and COPD Therapies Market: National Markets Forecast 2015-2025
4.4.1 How Will National Market Shares Change to 2025?
4.5 The US Asthma and COPD Therapies Market 2015-2025
4.5.1 US Asthma and COPD Therapies Market Forecast 2015-2025
4.5.2 US Asthma and COPD Therapies Market: Trends and Developments
4.5.2.1 Increasing COPD Prevalence in the US
4.5.2.2 FDA Issues Draft Guidance on Generic Inhaler Bioequivalence
4.5.2.3 Pharmacy Benefit Managers Alter Formulary Status of Advair
4.6 Japanese Asthma and COPD Therapies Market 2015-2025
4.6.1 Japanese Asthma and COPD Therapies Market Forecast 2015-2025
4.6.2 Japanese Asthma and COPD Therapies Market: Trends and Developments
4.6.2.1 Generic Penetration to Reach 60% by 2018?
4.6.2.2 Japanese Pharmaceutical Industry Regulatory Reform
4.7 EU5 Asthma and COPD Therapies Market 2015-2025
4.7.1 German Asthma and COPD Therapies Market Forecast 2015-2025
4.7.2 French Asthma and COPD Therapies Market Forecast 2015-2025
4.7.3 UK Asthma and COPD Therapies Market Forecast 2015-2025
4.7.4 Italian Asthma and COPD Therapies Market Forecast 2015-2025
4.7.5 Spanish Asthma and COPD Therapies Market Forecast 2015-2025
4.7.6 EU5 Asthma and COPD Therapies Market: Trends and Developments
4.7.6.1 Germany: Reform of AMNOG Pharmaceutical Rebate Law
4.7.6.2 France: Social Security Finance Bill 2015
4.7.6.3 UK: Improving Asthma and COPD Patient Outcomes
4.7.6.4 Italy: Austerity Measures Limiting Growth
4.7.6.5 Spain: The Start of Recovery in the Spanish Economy
4.8 BRIC Asthma and COPD Therapies Market 2015-2025
4.8.1 Chinese Asthma and COPD Therapies Market Forecast 2015-2025
4.8.2 Chinese Asthma and COPD Therapies Market: Trends and Developments
4.8.2.1 China’s Industrial Future and Asthma/COPD
4.8.2.2 Expansion of Healthcare Coverage and Reimbursement
4.8.2.3 Price Controls and the Anhui Model
4.8.3 Brazilian Asthma and COPD Therapies Market Forecast 2015-2025
4.8.4 Brazilian Asthma and COPD Therapies Market: Trends and Developments
4.8.4.1 Increasing Access to Medicines
4.8.5 Indian Asthma and COPD Therapies Market Forecast 2015-2025
4.8.6 Indian Asthma and COPD Therapies Market: Trends and Developments
4.8.6.1 Drug Prices Control Order 2014
4.8.6.2 Expansion of Healthcare Provision
4.8.7 Russian Asthma and COPD Therapies Market Forecast 2015-2025
4.8.8 Russian Asthma and COPD Therapies Market: Trends and Developments
4.8.8.1 No Embargo on Foreign Drug Imports
4.8.8.2 Pharma2020 and the Russian Pharmaceutical Industry
4.9 Mexican Asthma and COPD Therapies Market 2015-2025
4.9.1 Mexican Asthma and COPD Therapies Market Forecast 2015-2025
4.9.2 Mexican Asthma and COPD Therapies Market: Trends and Developments
4.9.2.1 Seguro Popular: Mexican Healthcare Reform
4.9.2.2 COFEPRIS: Regulatory Changes and Improvements
4.9.2.3 Mexico’s Agreement for Innovation
5. Bronchodilator Monotherapy Market 2015-2025
5.1 Introduction to Bronchodilator Monotherapy
5.2 The Bronchodilator Monotherapy Market in 2014
5.2.1 Leading Bronchodilators in 2014
5.3 Bronchodilator Monotherapy: Market Forecast 2015-2025
5.4 How Will Market Shares by Drug Class Change to 2025?
5.5 The Short-Acting Beta2-Agonist (SABA) Market 2015-2025
5.5.1 Leading SABAs in 2014
5.5.2 SABAs: Market Forecast 2015-2025
5.5.3 Market Share of Leading SABAs to 2025
5.5.4 Ventolin (salbutamol, GSK)
5.5.4.1 Ventolin: Sales Forecast 2015-2025
5.5.5 ProAir (salbutamol, Teva)
5.5.5.1 ProAir: Sales Forecast 2015-2025
5.5.6 Proventil (salbutamol, Merck)
5.5.6.1 Proventil: Sales Forecast 2015-2025
5.5.7 Xopenex (levosalbutamol, Dainippon Sumitomo)
5.5.7.1 Xopenex: Sales Forecast 2015-2025
5.6 The Long-Acting Beta2-Agonist (LABA) Market 2015-2025
5.6.1 Leading LABAs in 2014
5.6.2 LABAs: Market Forecast 2015-2025
5.6.3 Market Share of Leading LABAs to 2025
5.6.4 Foradil (formoterol, Merck/Novartis)
5.6.4.1 Foradil: Sales Forecast 2015-2025
5.6.5 Brovana (salmeterol, GSK)
5.6.5.1 Brovana: Sales Forecast 2015-2025
5.6.6 Arcapta/Onbrez (indacaterol, Novartis)
5.6.6.1 Arcapta/Onbrez: Sales Forecast 2015-2025
5.6.7 Serevent (arfomoterol, Dainippon Sumitomo)
5.6.7.1 Serevent: Sales Forecast 2015-2025
5.7 The Anticholinergics Market 2015-2025
5.7.1 Leading Anticholinergics in 2014
5.7.2 Anticholinergics: Market Forecast 2015-2025
5.7.3 Market Share of Leading Anticholinergics to 2025
5.7.4 Spiriva (tiotropium, Boehringer Ingelheim)
5.7.4.1 Spiriva: Sales Forecast 2015-2025
5.7.5 Spiriva: Recent Developments
5.7.5.1 Safety Concerns and the UPLIFT Trial
5.7.5.2 Results of the POET Study
5.7.5.3 Competition from Combination Products
5.7.6 Atrovent (ipratropium, Boehringer Ingelheim)
5.7.6.1 Atrovent: Sales Forecast 2015-2025
5.7.7 Eklira/Tudorza/Bretaris (aclidinium, AstraZeneca/Menarini)
5.7.7.1 Eklira/Tudorza/Bretaris: Sales Forecast 2015-2025
6. Anti-Inflammatory Drugs Market 2015-2025
6.1 Introduction to Anti-Inflammatory Drugs
6.2 The Anti-Inflammatory Drugs Market in 2014
6.2.1 Leading Anti-Inflammatory Drugs in 2014
6.3 Anti-Inflammatory Drugs: Market Forecast 2015-2025
6.4 How Will Market Shares by Drug Class Change to 2025?
6.5 The Corticosteroids Market 2015-2025
6.5.1 Leading Corticosteroids in 2014
6.5.2 Corticosteroids: Market Forecast 2015-2025
6.5.3 Market Share of Leading Corticosteroids to 2025
6.5.4 Flixotide/Flovent (fluticasone propionate, GSK)
6.5.4.1 Flixotide/Flovent: Sales Forecast 2015-2025
6.5.5 Pulmicort (budesonide, AstraZeneca)
6.5.5.1 Pulmicort: Sales Forecast 2015-2025
6.5.6 QVAR (beclometasone, Teva)
6.5.6.1 QVAR: Sales Forecast 2015-2025
6.5.7 Asmanex (mometasone, Merck)
6.5.7.1 Asmanex: Sales Forecast 2015-2025
6.6 The Anti-Leukotrienes Market 2015-2025
6.6.1 Leading Anti-Leukotrienes in 2014
6.6.2 Anti-Leukotrienes: Market Forecast 2015-2025
6.6.2.1 Market Share of Leading Anti-Leukotrienes to 2025
6.6.3 Singulair (montelukast, Merck)
6.6.3.1 Singulair: Sales Forecast 2015-2025
6.7 The Monoclonal Antibodies Market 2015-2025
6.7.1 Monoclonal Antibodies: Market Forecast 2015-2025
6.7.1.1 Market Share of Leading Monoclonal Antibodies to 2025
6.7.2 Xolair (omalizumab, Novartis/Roche)
6.7.2.1 Xolair: Sales Forecast 2015-2025
6.7.3 Cinquil (reslizumab, Teva)
6.7.3.1 Cinquil: Sales Forecast 2015-2025
6.7.4 Mepolizumab (Bosatria, GSK)
6.7.4.1 Mepolizumab: Sales Forecast 2015-2025
6.7.5 Benralizumab (MEDI-563, AstraZeneca/Kyowa Hakko Kirin)
6.7.5.1 Benralizumab: Sales Forecast 2015-2025
6.7.6 Lebrikizumab (RG3637, Roche)
6.7.6.1 Lebrikizumab: Sales Forecast 2015-2025
6.7.7 Dupilumab (REGN668, Regeneron/Sanofi)
6.7.7.1 Dupilumab: Sales Forecast 2015-2025
7. Combination Drugs Market 2015-2025
7.1 Introduction to Combination Drugs
7.1.1 Leading Combination Drugs in 2014
7.2 Combination Drugs: Market Forecast 2015-2025
7.3 How Will Market Shares by Drug Change to 2025?
7.3.1 Advair/Seretide (fluticasone/salmeterol, GSK)
7.3.1.1 Advair/Seretide: Sales Forecast 2015-2025
7.3.2 Symbicort (budesonide/formoterol fumarate, AstraZeneca)
7.3.2.1 Symbicort: Sales Forecast 2015-2025
7.3.2.2 Symbicort: The SMART Concept
7.3.3 Combivent (ipratropium/salbutamol, Boehringer Ingelheim)
7.3.3.1 Combivent: Sales Forecast 2015-2025
7.3.4 Dulera (formoterol/mometasone, Merck)
7.3.4.1 Dulera: Sales Forecast 2015-2025
7.3.5 Breo/Relvar Ellipta (vilanterol/fluticasone furoate, GSK)
7.3.5.1 Breo/Relvar: Sales Forecast 2015-2025
7.4 Recently Launched Combination Drugs
8. Leading Companies in the Asthma and COPD Therapies Market
8.1 Asthma and COPD Therapies: Increasing Competition
8.1.1 Leading Companies in Asthma and COPD in 2015
8.1.2 Leading Companies: Market Forecast 2015-2025
8.1.3 How Will Leading Companies’ Market Shares Change to 2025?
8.2 GSK
8.2.1 GSK: Asthma and COPD Therapies
8.2.2 GSK: Sales Forecast 2015-2025
8.2.3 GSK: Products in Development
8.2.4 GSK: Recent Developments
8.2.4.1 Recently Launched Combination Drugs
8.2.4.2 GSK Divests OTC Products
8.2.4.3 GSK Asset Swap with Novartis to Restructure Consumer Health
8.2.4.4 GSK Presents Data on Eosinophil Levels and COPD
8.3 Boehringer Ingelheim
8.3.1 Boehringer Ingelheim: Asthma and COPD Therapies
8.3.2 Boehringer Ingelheim: Sales Forecast 2015-2025
8.3.3 Boehringer Ingelheim: Asthma and COPD Product Development Ceased
8.3.4 Boehringer Ingelheim: Recent Developments
8.3.4.1 Expansion of Respimat Manufacturing Capacity
8.3.4.2 Respimat Safety Concerns and the TIOSPIR Study
8.3.4.3 Ben Venue Laboratories Shut Down
8.3.4.4 Sale of Roxane Laboratories
8.4 AstraZeneca
8.4.1 AstraZeneca: Asthma and COPD Therapies
8.4.2 AstraZeneca: Sales Forecast 2015-2025
8.4.3 AstraZeneca: Products in Development
8.4.4 AstraZeneca: Recent Developments
8.4.4.1 AstraZeneca Acquires Almirall’s Respiratory Portfolio
8.4.4.2 Acquisition of Pearl Therapeutics Expanded AstraZeneca’s Combination Drug Pipeline
8.4.4.3 AstraZeneca Rejects Pfizer Takeover Bid
8.4.4.4 AstraZeneca Acquires Right to Actavis’ Branded Respiratory Portfolio in US and Canada
8.5 Merck & Co. (Merck)
8.5.1 Merck: Asthma and COPD Therapies
8.5.2 Merck: Sales Forecast 2015-2025
8.5.3 Merck: Products in Development
8.5.4 Merck: Recent Developments
8.5.4.1 Bayer Acquires Merck’s Consumer Health Business
8.5.4.2 FDA Rejects Singulair OTC Switch
8.5.4.3 Takeda Ended Co-Promotion of Daxas with Merck
8.6 Novartis
8.6.1 Novartis: Asthma and COPD Therapies
8.6.2 Novartis: Sales Forecast 2015-2025
8.6.3 Novartis: Products in Development
8.6.4 Novartis: Recent Developments
8.6.4.1 Novartis Restructures Following Strategic Review
8.6.4.2 Novartis Presents Data on Ultibro and Seebri
8.6.4.3 Pfizer Promotes Two Novartis COPD drugs in the UK
8.7 Roche
8.7.1 Roche: Asthma and COPD Therapies
8.7.2 Roche: Sales Forecast 2015-2025
8.7.3 Roche: Products in Development
8.8 Teva
8.8.1 Teva: Asthma and COPD Therapies
8.8.2 Teva: Sales Forecast 2015-2025
8.8.3 Teva: Products in Development
8.8.4 Teva: Recent Developments
8.8.4.1 Launch of DuoResp Spiromax
9. Asthma and COPD Therapies Pipeline Analysis 2015-2025
9.1 A Strong Asthma and COPD Pipeline
9.2 The Bronchodilators Pipeline
9.2.1 Bronchodilators: Phase 3 Pipeline
9.2.1.1 PX1439 and PX1442 (Prosonix)
9.2.1.2 PT001 (glycopyrronium, AstraZeneca)
9.2.1.3 Spiriva Respimat (tiotropium, Boehringer Ingelheim)
9.2.1.4 GW642444 (vilanterol, GSK)
9.2.1.5 KRP-AB1102 (aclidinium, Kyorin Pharmaceutical)
9.2.1.6 Seebri Breezhaler (glycopyrronium, Novartis/Vectura)
9.2.1.7 QVAR BAI (beclometasone, Teva)
9.2.1.8 Albuterol MDPI/Albuterol Spiromax (salbutamol, Teva)
9.3 The Anti-Inflammatory Drugs Pipeline
9.3.1 Anti-Inflammatory Drugs: Phase 3 Pipeline
9.3.1.1 PSX1001 and PSX1050 (fluticasone propionate pMDI, Prosonix)
9.3.1.2 Masitinib (tyrosine kinase inhibitor, AB Science)
9.3.1.3 Inhaled Alpha-1 Antitrypsin (Kamada/Chiesi Farmaceutici)
9.3.1.4 VR506 (fluticasone propionate DPI, Vectura)
9.3.1.5 Favolir (budesonide, Vectura)
9.4 The Combination Drugs Pipeline
9.4.1 Combination Drugs: Phase 3 Pipeline
9.4.1.1 PSX2005 (fluticasone/salmeterol, Prosonix)
9.4.1.2 LAS40464 (aclidinium/formoterol, AstraZeneca)
9.4.1.3 PT003 (glycopyrronium/formoterol, AstraZeneca)
9.4.1.4 Tiotropium/Olodaterol Fixed-Dose Combination (LAMA/LABA, Boehringer Ingelheim)
9.4.1.5 Easyhaler Combination Drugs (Orion)
9.4.1.6 VR632 (ICS/LABA, Vectura/Sandoz)
9.5 Other Asthma and COPD Drugs Pipeline
10. Qualitative Analysis of the Asthma and COPD Therapies Market 2015-2025
10.1 SWOT Analysis of the Asthma and COPD Therapies Market
10.2 Strengths
10.2.1 Increasing Prevalence and Disease Burden
10.2.2 High Costs of Treatment
10.2.3 The Changing Perception of COPD
10.2.4 Patient Education: Understanding the Severity of Respiratory Disease
10.2.5 Lifecycle Management Strategies to Counter Patent Expiry
10.2.6 Advanced Inhaler Technologies to Counter Generic Erosion
10.2.7 Developments in Diagnostics
10.2.7.1 Diagnostic Imaging: Parametric Response Mapping for COPD
10.2.7.2 Biological Markers in COPD
10.3 Weaknesses
10.3.1 Under-Diagnosis: the ‘Ghost Population’
10.3.2 Side-Effects of Drug Classes
10.3.3 Patent Cliff for Devices
10.3.4 Low Patient Adherence
10.3.5 Costing Pressures in both Developed and Emerging Markets
10.4 Opportunities
10.4.1 Patient Phenotyping and Personalised Medicine
10.4.2 A Strong R&D Pipeline
10.4.2.1 Ultra-Long-Acting Beta2-Agonists
10.4.2.2 Muscarinic Antagonists and Beta2-Agonists (MABAs)
10.4.2.3 Monoclonal Antibodies
10.4.2.4 LAMA/LABA Combinations
10.4.3 Opportunities in Telehealth
10.5 Threats
10.5.1 Patent Expiry and Generic Competition
10.5.2 Pharmacy Benefit Managers and Cost Control
10.5.3 The WISDOM Trial Could Reduce Steroid Use in COPD
10.6 Porter’s Five Forces Analysis of the Asthma and COPD Therapies Market
10.6.1 Rivalry Among Competitors [Medium]
10.6.2 Threat of New Entrants [Medium]
10.6.3 Power of Suppliers [Medium]
10.6.4 Power of Buyers [High]
10.6.5 Threat of Substitutes [Low]
11. Research Interviews
11.1 Interview with Professor Clive Page, Professor of Pharmacology and Director of the Sackler Institute of Pulmonary Pharmacology, King’s College London
11.1.1 Treating Different Phenotypes of Asthma and COPD
11.1.2 Personalised Medicine and Improved Existing Drug Classes
11.1.3 Phenotyping of Asthma/COPD, Diagnosis and Treatment
11.1.4 WISDOM Trial: Questioning the Role of Steroids in COPD
11.1.5 Monoclonal Antibodies in Severe Asthma
11.1.6 Healthcare Costs and the Importance of Prevention
11.1.7 Areas to Improve Diagnosis and Treatment of Asthma
11.1.8 The Importance of Adherence and Early Diagnosis
11.1.9 Developments in Alpha-1 Antitrypsin Deficiency
11.1.10 Other Trends and Developments in Asthma and COPD
11.2 Interview with a Company Developing Pipeline Drugs for Asthma and COPD
11.2.1 Asthma and COPD Treatments in 2014-2024
11.2.2 Personalised Therapies for Asthma and COPD
11.2.3 Drivers and Restraints in the Market
11.2.4 The Outlook for the Asthma and COPD Market
12. Conclusions
12.1 Asthma and COPD Therapies: A Maturing Market
12.2 The World Asthma and COPD Therapies Market in 2014
12.2.1 Current Leading Asthma and COPD Therapies Segments
12.2.2 Leading Asthma and COPD Therapies
12.2.3 Leading Asthma and COPD Therapies Companies
12.2.4 Leading Regional and National Markets
12.3 World Asthma and COPD Therapies Market Forecast 2015-2025
12.4 The Future of the Asthma and COPD Therapies Market?
12.4.1 Growth in Anti-Inflammatory and Combination Drugs
12.4.2 Towards Personalised Medicine
12.4.3 Unmet Needs in Asthma and COPD
12.4.4 Strategies for Growth in 2015-2025
13. Glossary
Appendix A
Appendix B
【レポート販売概要】
■ タイトル：喘息及びCOPD（慢性閉塞性肺疾患）治療の世界市場予測：気管支拡張薬、抗炎症薬■ 英文：Asthma and COPD Therapies Market Forecast 2015-2025: Opportunities for Leading Companies
■ 発行日：2015年10月
■ 調査会社：visiongain
■ 商品コード：VGAIN5102610
■ 調査対象地域：グローバル
- 医療用超音波装置の世界市場2015-2019About Ultrasound Equipment Ultrasound equipment are used to examine organs using high-frequency sound waves. Ultrasound systems are extensively used by cardiologists, radiologists, surgeons, obstetricians, and many other healthcare professionals as they are considered to be safer than most other imaging techniques. Ultrasound equipment provide healthcare professionals with vital health-related inf …
- 金融産業における物理セキュリティ市場：監視装置、アクセス制御システム、クラウドサービス、セキュリティソフトウェアAbout Physical Security in BFSI Physical security involves securing an organization's data, hardware, network, and processes that can be damaged by an external agency, which in turn can damage its brand value. There are a number of hardware devices and software that are being adopted by government organizations and enterprises to ensure the physical security of critical data and infrastructure. In …
- プロセス分析計（液体＆ガス）、ガスクロマトグラフィーおよび分光法の世界市場予測（～2020）The global process analyzers (liquid & gas) market is expected to grow from USD 3.57 Billion in 2014 to USD 4.98 Billion by 2020, at a CAGR of 5.50% between 2015 and 2020. The market is majorly driven by the increase in the shale gas production in the U.S. and growing demand for water & wastewater treatment. In addition, increasing usage of process liquid and gas analyzers in the emerging markets …
- 液体洗剤の世界市場2017-2021About Liquid DetergentLiquid detergents are increasingly being used by consumers as they are easy to dilute and can be used in both cold and warm water. Technavio’s analysts forecast the global liquid detergent market to grow at a CAGR of 8.18% during the period 2017-2021. [Covered in this report] The report covers the present scenario and the growth prospects of the global liquid detergent market …
- トコトリエノールの世界市場分析：製品別（アルファ、ベータ、ガンマ、デルタ）、エンドユーザー別（サプリメント、医薬品、化粧品）、セグメント予測The global tocotrienol market is expected to reach USD 387.6 million by 2024, according to a new report by Grand View Research, Inc. Increasing penetration of tocotrienols in the pharmaceutical industry owing to properties such as anti-cancer and lowering triglyceride is expected remain a key driving factor over the forecast period. Vitamin E derived tocotrienol exhibits antioxidant properties tha …
- ハイヒールシューズの世界市場2019-2023About this market The demand for premium footwear is expected to rise rapidly owing to high disposable income and celebrity endorsements for various footwear brands. Advances in footwear manufacturing and innovative product designs also increase sales of premium footwear. These famous brands along with many regional players also manufacture customized high heel footwear for better customer satisfa …
- フィールドフォースオートメーション（FFA）の世界市場2016-2020About Field Force Automation FFA employs a combination of technologies to gather information in real time. The solution makes use of devices, such as PCs, tablets, mobile phones, PDAs, and wireless devices to collect and report data from the field to back-end systems (CRM, ERP, or accounting systems) through wireless connectivity. This allows constant updating of information directly from the fiel …
- 建築用塗料の世界市場2015-2019About commercial architectural coatings Commercial architectural coatings are products used to protect surfaces and/or enhance their appearance. Architectural coatings are applied to commercial and residential buildings. They protect a building from moisture, UV radiation, and microbes. Paints, primers, lacquers, varnishes, and stains are some of the primary types of architectural coating products …
- 世界の癒着防止バリア（医療機器）市場（2014-2018）An adhesion barrier or anti-adhesion is a medical device implanted to minimize adhesion by separating the internal tissues and organs during healing. Adhesion formation is a common post-surgical problem affecting more than 50 percent of patients undergoing surgeries. Adhesion can cause serious issues such as bowel obstruction, infertility, and chronic abdominal pain. General/abdominal surgery, pel …
- 高所作業車（AWPトラック）の世界市場2016-2020About Aerial Work Platform Truck AWPs are used at electrical and telecommunication infrastructure construction sites, where an elevated work platform is required and are supported by scissors, masts, or booms. These devices are easy to use and are typically safer when compared to scaffolds and ladders. They are usually powered by gas, electricity, pneumatic, or hydraulic systems. Technavio’s analy …
- 不妊治療サービスの米国市場2017-2021About Infertility Services Infertility is the failure to achieve pregnancy after 12 months of unprotected intercourse. Infertility occurs due to the abnormal functioning of the female and male reproductive system. It can be treated with infertility drugs and through procedures such as artificial insemination, in-vitro fertilization, and surrogacy. Technavio’s analysts forecast the infertility serv …
- 人工知能(AI)の世界市場2019-2023About this market The cybersecurity industry has recorded a growing number of fraud and malicious attacks, ranging from stealing personal data to important organizational information, in the past few years. Companies are looking to apply Al technologies to combat these threats more effectively. Al technology help in threat detection, pattern recognition, and response time reduction. It also helps …
- 血友病A・血友病Bの組換え因子補充療法：世界の薬剤市場予測・分析PharmaPoint: Hemophilia A and B Recombinant Factor Replacement Therapy - Global Drug Forecast and Market Analysis to 2024 Summary Congenital hemophilia A and B are bleeding disorders that are caused by genetic X-linked deficiencies in the blood clotting Factors VIII and IX, respectively. Hemophilia manifests as mild, moderate, or severe inability to form clots, depending upon the endogenous levels …
- 世界の5G無線通信エコシステム：技術、アプリケーション、産業、戦略、市場予測While LTE and LTE-Advanced deployments are still underway, wireless carriers and vendors have already embarked on R&D initiatives to develop so-called “5G” technology, with a vision of commercialization by 2020. 5G is essentially a revolutionary paradigm shift in wireless networking to support the throughput, latency, and scalability requirements of future use cases such as extreme bandwidth augme …
- 企業向けEラーニングの世界市場：コンテンツ、技術、サービスAbout Corporate E-learning Enterprises of different sizes have started considering e-learning as a viable solution to issues related to their budget and productivity. Changing business needs and advances in technology have encouraged the adoption of e-learning solutions among enterprises. The introduction of SMAC (social, mobile, analytics, and cloud) technologies has also facilitated the adoption …
